Provided by Tiger Trade Technology Pte. Ltd.

Johnson & Johnson

235.65
+0.28000.12%
Volume:3.62M
Turnover:852.18M
Market Cap:567.75B
PE:21.36
High:238.31
Open:237.06
Low:234.25
Close:235.37
52wk High:251.71
52wk Low:141.50
Shares:2.41B
Float Shares:2.40B
Volume Ratio:0.48
T/O Rate:0.15%
Dividend:5.14
Dividend Rate:2.18%
EPS(TTM):11.03
EPS(LYR):11.03
ROE:35.03%
ROA:8.68%
PB:6.96
PE(LYR):21.36

Loading ...

TuHURA Biosciences names Craig Tendler to CMO-like role while he remains on board

Reuters
·
Yesterday

Press Release: Craig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related Cancers

Dow Jones
·
Yesterday

Is It Too Late To Consider Johnson & Johnson (JNJ) After A 49.8% One-Year Surge?

Simply Wall St.
·
Mar 20

Perrigo Co. PLC Stock Underperforms Thursday When Compared To Competitors

Dow Jones
·
Mar 20

Origin Materials names HP Embalagens as distributor for sustainable PET bottlecaps

Reuters
·
Mar 20

Protagonist's Oral Peptide Platform Validated With Icotyde Approval for Psoriasis, Wedbush Says

MT Newswires Live
·
Mar 20

Johnson & Johnson Is Maintained at Equal-Weight by Barclays

Dow Jones
·
Mar 19

Analysts Offer Insights on Healthcare Companies: Alto Neuroscience, Inc. (ANRO), Johnson & Johnson (JNJ) and InspireMD (NSPR)

TIPRANKS
·
Mar 19

Johnson & Johnson-Protagonist Therapeutics Partnered New Psoriasis Pill Wins FDA Nod, Shakes Up Competition With AbbVie

Benzinga_recent_news
·
Mar 19

Early Icotyde Approval Strengthens Johnson & Johnson’s Immunology Growth Outlook and Multi‑Billion‑Dollar Potential

TIPRANKS
·
Mar 19

Johnson & Johnson : Barclays Raises Target Price to $234 From $217

THOMSON REUTERS
·
Mar 19

Johnson & Johnson price target raised to $234 from $217 at Barclays

TIPRANKS
·
Mar 19

Barclays Adjusts Price Target on Johnson & Johnson to $234 From $217, Maintains Equalweight Rating

MT Newswires Live
·
Mar 19

BNP Paribas: J&J's New Psoriasis Drug Enters Market, Posing Challenge to AbbVie's Blockbuster Skyrizi

Stock News
·
Mar 19

Perrigo Co. PLC Stock Underperforms Wednesday When Compared To Competitors

Dow Jones
·
Mar 19

BUZZ-AbbVie falls as J&J psoriasis pill raises competition risk

Reuters
·
Mar 19

REFILE-US STOCKS-Wall Street remains lower after Fed keeps rates unchanged

Reuters
·
Mar 19

Abbvie Shares Down 3.2% After US FDA Approves Johnson & Johnson's Oral Psoriasis Pill

THOMSON REUTERS
·
Mar 18

BUZZ-Protagonist climbs after FDA approves oral psoriasis drug

Reuters
·
Mar 18

Shares of Protagonist Therapeutics Rise 4% Premarket After U.S. FDA Approves Co's, Johnson & Johnson’s Oral Psoriasis Drug

THOMSON REUTERS
·
Mar 18